Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

Abstract:

Importance:Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast cancer (TNBC). Objective:To investigate the effect of capecitabine on long-term survival outcomes of patients with early breast cancer, particularly in subgroups defined by cancer estrogen receptor (ER) and progesterone receptor (PR) content, and HER2 content (human epidermal growth factor receptor 2). Design, Setting, and Participants:This is an exploratory analysis of the multicenter FinXX randomized clinical trial that accrued 1500 women in Finland and Sweden between January 27, 2004, and May 29, 2007. About half received 3 cycles of docetaxel followed by 3 cycles of cyclophosphamide, epirubicin, and fluorouracil (T+CEF), while the other half received 3 cycles of docetaxel plus capecitabine followed by 3 cycles of cyclophosphamide, epirubicin, and capecitabine (TX+CEX). Data analysis took place between January 27, 2004, and December 31, 2015. Main Outcomes and Measures:Recurrence-free survival (RFS). Results:Following random allocation, 747 women received T+CEF, and 753 women received TX+CEX. Five patients were excluded from the intention-to-treat population (3 had overt distant metastases at the time of randomization; 2 withdrew consent). The median age of the remaining 1495 patients was 53 years at the time of study entry; 157 (11%) had axillary node-negative disease; 1142 (76%) had ER-positive cancer; and 282 (19%) had HER2-positive cancer. The median follow-up time after random allocation was 10.3 years. There was no significant difference in RFS or overall survival between the groups (hazard ratio [HR], 0.88; 95% CI, 0.71-1.08; P = .23; and HR, 0.84, 95% CI, 0.66-1.07; P = .15; respectively). Breast cancer-specific survival tended to favor the capecitabine group (HR, 0.79; 95% CI, 0.60-1.04; P = .10). When RFS and survival of the patients were compared within the subgroups defined by cancer steroid hormone receptor status (ER and/or PR positive vs ER and PR negative) and HER2 status (positive vs negative), TX+CEX was more effective than T+CEF in the subset of patients with TNBC (HR, 0.53; 95% CI, 0.31-0.92; P = .02; and HR, 0.55, 95% CI, 0.31-0.96; P = .03; respectively). Conclusions and Relevance:Capecitabine administration with docetaxel, epirubicin, and cyclophosphamide did not prolong RFS or survival compared with a regimen that contained only standard agents. Patients with TNBC had favorable survival outcomes when treated with the capecitabine-containing regimen in an exploratory subgroup analysis. Trial Registration:clinicaltrials.gov Identifier: NCT00114816.

journal_name

JAMA Oncol

journal_title

JAMA oncology

authors

Joensuu H,Kellokumpu-Lehtinen PL,Huovinen R,Jukkola-Vuorinen A,Tanner M,Kokko R,Ahlgren J,Auvinen P,Lahdenperä O,Kosonen S,Villman K,Nyandoto P,Nilsson G,Poikonen-Saksela P,Kataja V,Junnila J,Bono P,Lindman H

doi

10.1001/jamaoncol.2016.6120

subject

Has Abstract

pub_date

2017-06-01 00:00:00

pages

793-800

issue

6

eissn

2374-2437

issn

2374-2445

pii

2606438

journal_volume

3

pub_type

杂志文章,多中心研究,随机对照试验
  • Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia.

    abstract:Importance:Esophageal adenocarcinoma and its precursor lesion Barrett esophagus have seen a dramatic increase in incidence over the past 4 decades yet marked genetic heterogeneity of this disease has precluded advances in understanding its pathogenesis and improving treatment. Objective:To identify novel disease susce...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.2054

    authors: Fecteau RE,Kong J,Kresak A,Brock W,Song Y,Fujioka H,Elston R,Willis JE,Lynch JP,Markowitz SD,Guda K,Chak A

    更新日期:2016-10-01 00:00:00

  • The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials.

    abstract:IMPORTANCE:Positive phase 3 cancer clinical trials are widely hailed, while trials with negative results are often interpreted as scientific failures. We hypothesized that these interpretations would be reflected in the scientific literature. OBJECTIVE:To compare the scientific impact of positive vs negative phase 3 c...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6487

    authors: Unger JM,Barlow WE,Ramsey SD,LeBlanc M,Blanke CD,Hershman DL

    更新日期:2016-07-01 00:00:00

  • Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.

    abstract:Importance:The role of epidermal growth factor receptor (EGFR) inhibition in chemoradiation strategies in the nonoperative treatment of patients with esophageal cancer remains uncertain. Objective:To evaluate the benefit of cetuximab added to concurrent chemoradiation therapy for patients undergoing nonoperative treat...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2017.1598

    authors: Suntharalingam M,Winter K,Ilson D,Dicker AP,Kachnic L,Konski A,Chakravarthy AB,Anker CJ,Thakrar H,Horiba N,Dubey A,Greenberger JS,Raben A,Giguere J,Roof K,Videtic G,Pollock J,Safran H,Crane CH

    更新日期:2017-11-01 00:00:00

  • Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.

    abstract:Importance:Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H). Objective:To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated pro...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2020.0910

    authors: Chen EX,Jonker DJ,Loree JM,Kennecke HF,Berry SR,Couture F,Ahmad CE,Goffin JR,Kavan P,Harb M,Colwell B,Samimi S,Samson B,Abbas T,Aucoin N,Aubin F,Koski SL,Wei AC,Magoski NM,Tu D,O'Callaghan CJ

    更新日期:2020-06-01 00:00:00

  • Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.

    abstract:Importance:Epidermal growth factor receptor (EGFR) (HER1) signaling depends on ligand binding and dimerization with itself or other HER receptors. We previously showed in a randomized trial that high EGFR ligand expression is predictive of panitumumab benefit in advanced colorectal cancer. Tumor expression of HER3 may ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2017.3168

    authors: Seligmann JF,Hatch AJ,Richman SD,Elliott F,Jacobs B,Brown S,Hurwitz H,Barrett JH,Quirke P,Nixon AB,Seymour MT

    更新日期:2018-04-01 00:00:00

  • Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

    abstract:Importance:To date, the benefit of genome-driven cancer therapy has not been quantified. Objective:We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approved genome-driven ther...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1660

    authors: Marquart J,Chen EY,Prasad V

    更新日期:2018-08-01 00:00:00

  • Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer.

    abstract:Purpose:To harmonize the eligibility criteria and radiologic disease assessment definitions in clinical trials of adjuvant therapy for renal cell carcinoma (RCC). Method:On November 28, 2017, US-based experts in RCC clinical trials, including medical oncologists, urologic oncologists, regulators, biostatisticians, rad...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.4117

    authors: Agrawal S,Haas NB,Bagheri M,Lane BR,Coleman J,Hammers H,Bratslavsky G,Chauhan C,Kim L,Krishnasamy VP,Marko J,Maher VE,Ibrahim A,Cross F Jr,Liu K,Beaver JA,Pazdur R,Blumenthal GM,Singh H,Plimack ER,Choueiri TK,Uz

    更新日期:2019-11-21 00:00:00

  • Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

    abstract:Importance:A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine therapy alone, and for chemotherapy benefit. Objective:To describe clinical outcomes for women with a high RS who received adjuvant chemotherapy plus endo...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2019.4794

    authors: Sparano JA,Gray RJ,Makower DF,Albain KS,Saphner TJ,Badve SS,Wagner LI,Kaklamani VG,Keane MM,Gomez HL,Reddy PS,Goggins TF,Mayer IA,Toppmeyer DL,Brufsky AM,Goetz MP,Berenberg JL,Mahalcioiu C,Desbiens C,Hayes DF,Dees

    更新日期:2020-03-01 00:00:00

  • Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women.

    abstract:Importance:The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover effect exists, with risk reduction before and risk increase after menopause. The inverse association w...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.1771

    authors: Premenopausal Breast Cancer Collaborative Group.,Schoemaker MJ,Nichols HB,Wright LB,Brook MN,Jones ME,O'Brien KM,Adami HO,Baglietto L,Bernstein L,Bertrand KA,Boutron-Ruault MC,Braaten T,Chen Y,Connor AE,Dorronsoro M,Dossu

    更新日期:2018-11-01 00:00:00

  • Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

    abstract:Importance:Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promising results for these patient...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2019.0250

    authors: He M,Li Q,Zou R,Shen J,Fang W,Tan G,Zhou Y,Wu X,Xu L,Wei W,Le Y,Zhou Z,Zhao M,Guo Y,Guo R,Chen M,Shi M

    更新日期:2019-07-01 00:00:00

  • Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.

    abstract:Importance:The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history of or risk factors for seizure were excluded. Men with mCRPC and s...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2017.3361

    authors: Slovin S,Clark W,Carles J,Krivoshik A,Park JW,Wang F,George D

    更新日期:2018-05-01 00:00:00

  • Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

    abstract:IMPORTANCE:Substantial progress has been made in cancer diagnosis and treatment, resulting in a steady improvement in cancer survival. The degree of improvement by age, race, and sex remains unclear. OBJECTIVE:To quantify the degree of survival improvement over time by age, race, and sex in the United States. DESIGN,...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2014.161

    authors: Zeng C,Wen W,Morgans AK,Pao W,Shu XO,Zheng W

    更新日期:2015-04-01 00:00:00

  • Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.

    abstract:Importance:Randomized trials in breast cancer have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in preventing recurrence and death. The examination of concordance with AET guidelines at a national level as a measure of quality of care is important. Objective:To investigate temporal trends and...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6380

    authors: Daly B,Olopade OI,Hou N,Yao K,Winchester DJ,Huo D

    更新日期:2017-07-01 00:00:00

  • Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.

    abstract:Importance:The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity. Objective:To compare 6 cycles of paclitaxel plus carboplatin (PCb) wi...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2965

    authors: Yu KD,Ye FG,He M,Fan L,Ma D,Mo M,Wu J,Liu GY,Di GH,Zeng XH,He PQ,Wu KJ,Hou YF,Wang J,Wang C,Zhuang ZG,Song CG,Lin XY,Toss A,Ricci F,Shen ZZ,Shao ZM

    更新日期:2020-09-01 00:00:00

  • Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.

    abstract:Importance:Although adjuvant endocrine therapy confers a survival benefit among females with hormone receptor (HR)-positive breast cancer, the effectiveness of this treatment among males with HR-positive breast cancer has not been rigorously investigated. Objective:To investigate trends, patterns of use, and effective...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1114

    authors: Venigalla S,Carmona R,Guttmann DM,Jain V,Freedman GM,Clark AS,Shabason JE

    更新日期:2018-10-01 00:00:00

  • Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

    abstract:Importance:Tumor-treating fields (TTFields) therapy improves both progression-free and overall survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients' health-related quality of life (HRQoL). Objective:To examine the association of TTFields therapy with progression-free ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2017.5082

    authors: Taphoorn MJB,Dirven L,Kanner AA,Lavy-Shahaf G,Weinberg U,Taillibert S,Toms SA,Honnorat J,Chen TC,Sroubek J,David C,Idbaih A,Easaw JC,Kim CY,Bruna J,Hottinger AF,Kew Y,Roth P,Desai R,Villano JL,Kirson ED,Ram Z,

    更新日期:2018-04-01 00:00:00

  • Association of a Bundled-Payment Program With Cost and Outcomes in Full-Cycle Breast Cancer Care.

    abstract:Importance:Value-driven payment system reform is a potential tool for aligning economic incentives with the improvement of quality and efficiency of health care and containment of cost. Such a payment system has not been researched satisfactorily in full-cycle cancer care. Objective:To examine the association of outco...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.4549

    authors: Wang CJ,Cheng SH,Wu JY,Lin YP,Kao WH,Lin CL,Chen YJ,Tsai SL,Kao FY,Huang AT

    更新日期:2017-03-01 00:00:00

  • Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.

    abstract:Importance:Axicabtagene ciloleucel, an anti-CD19-CD28-CD3ζ chimeric antigen receptor T-cell therapy, was the first US Food and Drug Administration-approved, genetically engineered T-cell therapy for adults with relapsed or refractory large B-cell lymphoma (LBCL) after 2 or more lines of systemic therapy. There has not ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2019.3869

    authors: Locke FL,Go WY,Neelapu SS

    更新日期:2020-02-01 00:00:00

  • Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.

    abstract:Importance:Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary malignant neoplasm (PM) by age. Objective:To assess the survival impact of SPMs in...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.0465

    authors: Keegan THM,Bleyer A,Rosenberg AS,Li Q,Goldfarb M

    更新日期:2017-11-01 00:00:00

  • Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.

    abstract:IMPORTANCE:E-cadherin (CDH1) is a cancer predisposition gene mutated in families meeting clinically defined hereditary diffuse gastric cancer (HDGC). Reliable estimates of cancer risk and spectrum in germline mutation carriers are essential for management. For families without CDH1 mutations, genetic-based risk stratif...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2014.168

    authors: Hansford S,Kaurah P,Li-Chang H,Woo M,Senz J,Pinheiro H,Schrader KA,Schaeffer DF,Shumansky K,Zogopoulos G,Santos TA,Claro I,Carvalho J,Nielsen C,Padilla S,Lum A,Talhouk A,Baker-Lange K,Richardson S,Lewis I,Lindor N

    更新日期:2015-04-01 00:00:00

  • The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.

    abstract:IMPORTANCE:Time to events, or survival end points, are common end points in randomized clinical trials. They are usually analyzed under the assumption of proportional hazards, and the treatment effect is reported as a hazard ratio, which is neither an intuitive measure nor a meaningful one if the assumption of proporti...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6359

    authors: Péron J,Roy P,Ozenne B,Roche L,Buyse M

    更新日期:2016-07-01 00:00:00

  • Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.

    abstract:Importance:Approximately 50% of the risk for the development of testicular germ cell tumors (TGCTs) is estimated to be heritable, but no mendelian TGCT predisposition genes have yet been identified. It is hypothesized that inherited pathogenic DNA repair gene (DRG) alterations may drive susceptibility to TGCTs. Object...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.6477

    authors: AlDubayan SH,Pyle LC,Gamulin M,Kulis T,Moore ND,Taylor-Weiner A,Hamid AA,Reardon B,Wubbenhorst B,Godse R,Vaughn DJ,Jacobs LA,Meien S,Grgic M,Kastelan Z,Markt SC,Damrauer SM,Rader DJ,Kember RL,Loud JT,Kanetsky PA,

    更新日期:2019-04-01 00:00:00

  • Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

    abstract:Importance:The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and the clinical utility of...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5801

    authors: Abida W,Cheng ML,Armenia J,Middha S,Autio KA,Vargas HA,Rathkopf D,Morris MJ,Danila DC,Slovin SF,Carbone E,Barnett ES,Hullings M,Hechtman JF,Zehir A,Shia J,Jonsson P,Stadler ZK,Srinivasan P,Laudone VP,Reuter V,Wo

    更新日期:2019-04-01 00:00:00

  • Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma.

    abstract:Importance:The risk stratification of adrenocortical carcinoma (ACC) based on tumor proliferation index and stage is limited. Adjuvant therapy after surgery is recommended for most patients. Pan-genomic studies have identified distinct molecular groups closely associated with outcome. Objective:To compare the molecula...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.1558

    authors: Assié G,Jouinot A,Fassnacht M,Libé R,Garinet S,Jacob L,Hamzaoui N,Neou M,Sakat J,de La Villéon B,Perlemoine K,Ragazzon B,Sibony M,Tissier F,Gaujoux S,Dousset B,Sbiera S,Ronchi CL,Kroiss M,Korpershoek E,De Krijger

    更新日期:2019-07-11 00:00:00

  • Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.

    abstract:Importance:While adjuvant hormonal therapy (HT) reduces mortality for women with nonmetastatic breast cancer, nonadherence to HT is common. Objective:We investigated the association between patterns of prior nonadherence to medications for chronic conditions with HT nonadherence. Design, Setting, and Participants:For...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.1291

    authors: Neugut AI,Zhong X,Wright JD,Accordino M,Yang J,Hershman DL

    更新日期:2016-10-01 00:00:00

  • A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.

    abstract:Importance:Multiparametric magnetic resonance imaging (MRI) in conjunction with MRI-transrectal ultrasound (TRUS) fusion-guided biopsies have improved the detection of prostate cancer. It is unclear whether MRI itself adds additional value to multivariable prediction models based on clinical parameters. Objective:To d...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.5667

    authors: Mehralivand S,Shih JH,Rais-Bahrami S,Oto A,Bednarova S,Nix JW,Thomas JV,Gordetsky JB,Gaur S,Harmon SA,Siddiqui MM,Merino MJ,Parnes HL,Wood BJ,Pinto PA,Choyke PL,Turkbey B

    更新日期:2018-05-01 00:00:00

  • Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.

    abstract:Importance:Administration of anti-programmed cell death protein 1 (anti-PD-1) is now standard therapy in advanced non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors, including anti-PD-1, have not been assessed in patients with subclinical disease with advanced NSCLC, and no useful clinical biomar...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5860

    authors: Toi Y,Sugawara S,Sugisaka J,Ono H,Kawashima Y,Aiba T,Kawana S,Saito R,Aso M,Tsurumi K,Suzuki K,Shimizu H,Domeki Y,Terayama K,Nakamura A,Yamanda S,Kimura Y,Honda Y

    更新日期:2019-03-01 00:00:00

  • Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

    abstract:Importance:Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. Objective:To assess the benefit of ADT plus docetaxel in patients presenting with rising prostate-specific ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2018.6607

    authors: Oudard S,Latorzeff I,Caty A,Miglianico L,Sevin E,Hardy-Bessard AC,Delva R,Rolland F,Mouret L,Priou F,Beuzeboc P,Gravis G,Linassier C,Gomez P,Voog E,Muracciole X,Abraham C,Banu E,Ferrero JM,Ravaud A,Krakowski I,L

    更新日期:2019-05-01 00:00:00

  • Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer.

    abstract:Importance:Conventional adjuvant radiotherapy for breast cancer given daily for several weeks is onerous and expensive. Some patients may be obliged to choose a mastectomy instead, and some may forgo radiotherapy altogether. We proposed a clinical trial to test whether radiotherapy could be safely limited to the tumor ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2020.0249

    authors: Vaidya JS,Bulsara M,Saunders C,Flyger H,Tobias JS,Corica T,Massarut S,Wenz F,Pigorsch S,Alvarado M,Douek M,Eiermann W,Brew-Graves C,Williams N,Potyka I,Roberts N,Bernstein M,Brown D,Sperk E,Laws S,Sütterlin M,Lu

    更新日期:2020-07-01 00:00:00

  • Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

    abstract:IMPORTANCE:Objective response rate (ORR) is an increasingly important end point for accelerated development of highly active anticancer therapies, yet its relationship to regulatory approval is not well characterized. OBJECTIVE:To identify circumstances in which a high ORR is associated with regulatory approval, and t...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.6315

    authors: Oxnard GR,Wilcox KH,Gonen M,Polotsky M,Hirsch BR,Schwartz LH

    更新日期:2016-06-01 00:00:00